SGLT2 inhibitors × adverse events & safety

SynthesisBMJ open2016

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.

Deepson S Shyangdan et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2016

Not counted

Probably lowered adverse events & safety

−37%−52% to −15%

Bigger than 7 in 10 for adverse events & safety

As reported

RR 0.63, 95% CI 0.48–0.85

One number in the abstract

the abstract, start to end

to 0.87%) and dapagliflozin 10 mg (RR 0.63, 95% CrI 0.48 to 0.85) but

← favours treatmentfavours comparator →
could be chance
Adverse events & safety
RR 0.630.48–0.85
SGLT2 inhibitorsAdverse events & safety
1 / 3

64 papers cite itlatest 60 shown

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 26911584